Granulin-epithelin precursor (GEP/progranulin) is an autocrine growth factor for ovarian cancer. We examined the production and function of GEP and report that: (1) GEP production is regulated by endothelin (ET-1), lysophosphatidic acid (LPA), and cAMP; (2) cAMP signals GEP production through exchange protein activated by cAMP (EPAC); (3) ET-1 and cAMP/EPAC induce GEP through ERK1/2; and (4) neutralization of GEP results in apoptosis. Exposure of HEY-A8 and OVCAR3 ovarian cancer cells to LPA and ET-1 yielded GEP production and secretion in a dose-and timedependent fashion; neither stimulated significant concentrations of cAMP directly. Stimulation of cAMP production with pertussis and cholera toxin, or forskolin induced GEP in a PKA-independent fashion. EPAC, an intracellular cAMP receptor, is activated specifically by the cAMP analog, 8-CPT-2 0 -O-Me-cAMP (8-CPT); 8-CPT treatment stimulated GEP production and secretion. The MEK inhibitor, U0126, abrogated GEP production in response to ET-1 and 8-CPT, confirming involvement of MAPK. A partial inhibition of basal and stimulated GEP production was observed when cells were treated with a internal calcium chelator, BAPTA. Neutralizing anti-GEP antibody reversed basal as well as LPA, ET-1 and 8-CPT-induced ovarian cancer cell growth and induced apoptosis as demonstrated by caspase-3 and PARP cleavage, DNA fragmentation, and nuclear condensation. These results indicate that GEP is a growth and survival factor for ovarian cancer, induced by LPA and ET-1 and cAMP/EPAC through ERK1/2. Oncogene (2005) 24, 7084-7093.
Introduction
Advances in the treatment of epithelial ovarian cancer have led to improvements in its 5-year median survival. However, despite these improvements, ovarian cancer remains the most lethal gynecologic malignancy in the United States, accounting for over 16 000 deaths annually (Jemal et al., 2004) . We previously identified overexpression of granulin-epithelin precursor (GEP/ progranulin) in the epithelium of invasive ovarian tumors in a global unbiased comparison of cDNA libraries generated from microdissected tumor cells and confirmed the results by RT-PCR and immunohistochemistry (Jones et al., 2003) . Antisense expression of GEP in cultured ovarian cancer cells inhibited monolayer and anchorage-independent growth, suggesting that GEP may play a role as an autocrine growth factor for ovarian cancer.
GEP is a 68 kDa protein with multiple polyglycosylated higher molecular weight isoforms of varying relative expression levels (Bateman et al., 1990; Bateman and Bennett, 1998; Jones et al., 2003) . It is a precursor protein that may also be cleaved into a series of cysteine-rich 6 kDa epithelins/granulins that have may have inhibitory activity (Bateman et al., 1990; Bateman and Bennett, 1998) . GEP, the precursor protein, has been reported to be an autocrine growth factor for highly tumorigenic PC murine-teratoma cells (Zhou et al., 1993; Zhang and Serrero, 1998) , breast cancer cells (Lu and Serrero, 1999 , and ovarian cancer cells (Jones et al., 2003) . Our studies and others have shown it to be involved in multiple steps of the tumor progression cascade including cellular proliferation, anchorage independence, invasiveness, resistance to anoikis, and promotion of resistance to select cytotoxic drugs (Bagnato et al., 1997; ZanoccoMarani et al., 1999; He and Bateman, 2003; Mills and Moolenaar, 2003) . GEP is also produced by stroma (Zhu et al., 2002; He et al., 2003; Jones et al., 2003) and has proangiogenic activity in wound-healing in vitro and in vivo models . The mechanisms underlying its production and activity have not been elucidated.
We hypothesized that GEP production may result from activation of stimulatory loops in ovarian cancer growth, invasion, and survival. Both lysophosphatidic acid (LPA) and endothelin-1 (ET-1) function as autocrine growth factors in ovarian cancer and both signal through G protein-coupled receptors (Bagnato et al., 1999; Vacca et al., 2000; Mills and Moolenaar, 2003) . Induction of GEP by LPA and ET-1 ligand-receptor activation may be a mechanism through which their activity is either propagated and/or augmented. We examined the production and regulation of GEP determining that (1) GEP is under the positive regulation of LPA and ET-1; (2) GEP production occurs in response to activation of the cAMP/exchange protein activated by cAMP (EPAC)/MAPK signaling pathway; and (3) GEP is necessary for ovarian cancer cell survival.
Results

LPA and ET-1 stimulate GEP expression
We hypothesized that GEP is produced in response to LPA and ET-1 growth factor treatment of ovarian cancer cells in order to propagate and/or amplify their proliferative and prosurvival signals (Bagnato et al., 1999; Del Bufalo et al., 2002a, b; Mills and Moolenaar, 2003; Nicosia et al., 2003) . HEY-A8 human ovarian cancer cells were treated with increasing concentrations of LPA resulting in a dose-and time-dependent stimulation of GEP gene expression and protein production ( Figure 1 ). Maximal stimulation was achieved at 20 mM LPA, a concentration physiologically observed in the ascites of ovarian cancer patients (Mills and Moolenaar, 2003) . Cells treated with 20 mM LPA were assessed over a 42 h exposure showing GEP protein expression increased in a time-dependent manner. Increased GEP also was detected in conditioned medium (Figure 1b, bottom panel) . HEY-A8 and OVCAR3 cells were exposed to increasing concentrations of ET-1 for 24-h, resulting in a dose-dependent stimulation of GEP protein expression with maximal stimulation achieved at 50 nM (Figure 1c, d ). Maximal GEP secretion was found in conditioned medium at 10 and 50 nM ET-1 in HEY-A8 and OVCAR3 cells, respectively.
GEP induction occurs through cAMP signaling in a PKA-independent fashion LPA and ET-1 are both ligands for G protein-coupled receptors that signal through the cAMP and/or MAPK pathways (Daub et al., 1996; Mills and Moolenaar, . HEY-A8 and OVCAR3 cells were treated with modulators of the cAMP pathway to map signaling events involved in GEP production. Treatment with pertussis toxin (PTX), an inhibitor of the inhibitory G ai subunit, cholera toxin (CTX), a stabilizer of the G as stimulatory subunit, and forskolin, a direct activator of adenylyl cyclase, each stimulated GEP production (Figure 2a-c) . This effect was further enhanced with the inclusion of the phosphodiesterase inhibitor, IBMX (data not shown). All were effective in a dose-dependent manner with maximal stimulatory response at 0.5 mg/ml for PTX and CTX and 13 mM forskolin in the cell, and 5 mg/ml CTX and 13 mM forskolin for conditioned medium. These results indicate that GEP production can occur downstream of G-protein-coupled receptor signaling. This led to the question, does LPA signal directly to cAMP, through ET-1 to cAMP, or not at all in the ovarian cancer cells. LPA 20 mM induced small quantities of ET-1 (0.2 pM) and doubled the basal cAMP (0.37 to 1.05 nM; Po0.001) in OVCAR3 cells, but induced neither ET-1 nor cAMP in HEY-A8 cells. Forskolin induced cAMP in both cell lines (HEY-A8: twofold, Po0.0001; OVCAR3: >5-fold, Po0.001). As there are adenylate cyclases that are either stimulated or inhibited by free cytosolic calcium, cells were treated with BAPTA to chelate free intracellular calcium (Zanassi et al., 2001; Guirland et al., 2003; Keiper et al., 2004) . This approach used a prolonged exposure to a low dose of BAPTA (1 mM for 1 h followed by 0.5 mM for up to 14 h), and found it was nontoxic for up to 12-14 h, a time frame in which induction of GEP by LPA, 8-CTP, and ET-1 has been initiated but is not readily observed. Figure 2d shows that treatment with BAPTA reduces basal and stimulated production of GEP. These results suggest that the ovarian cancer cells may have multiple methods of signaling to GEP production.
PKA is the primary intracellular cAMP receptor (Kopperud et al., 2003) and H89 is an effective and specific inhibitor of PKA. Treatment of HEY-A8 and OVCAR3 cells with concentrations of H89 up to 10 mM, a dose defined to inhibit PKA (Shabb and Corbin, 1990) , did not inhibit GEP production (Figure 2d ). Paradoxically, H89 treatment resulted in a dosedependent stimulation of cellular and secreted GEP production in both cell lines. This suggests that the cAMP-stimulated GEP production occurs through a PKA-independent cAMP-mediated signaling cascade.
Activation of the cAMP/EPAC/MAPK pathway stimulates GEP protein production EPAC, exchange protein activated by cAMP, is the second identified intracellular cAMP receptor (Bos, 2003; Kang et al., 2003; Rangarajan et al., 2003) . cAMP stimulates EPAC, activating the MAPK cascade (Enserink et al., 2002; Keiper et al., 2004) 
, is a selective ligand for EPAC (Kang et al., 2003) . Treatment of HEY-A8 and OVCAR3 cells with increasing concentrations of 8-CPT yielded a dose-and time-dependent increase in GEP production in lysate and conditioned medium (CM) (Figure 3 and data not shown). Maximal stimulatory responses were observed at 300 mM 8-CPT for 48 h. Exposure to U0126, a specific inhibitor of mitogen-activated protein kinase kinase, markedly cAMP/EPAC, ET-1, and LPA-mediated growth and survival are abrogated by neutralizing anti-GEP antibody Demonstration that LPA, ET-1, and 8-CPT produce bioactive GEP was obtained using neutralizing polyclonal anti-GEP antibodies. A small but statistically significant induction of growth measured by XTT assay is shown for 8-CPT, ET-1, and LPA (Pp0.01; Figure 5 ). Both basal and stimulated growth were markedly inhibited by inclusion of either antipeptide antibody, Ab736 or Ab737. The reduction of proliferation by the antibodies well below control levels led to the hypothesis that GEP was also important for survival signals. Both anti-GEP antibodies induced apoptosis, as shown by cleavage of caspase-3 and PARP in both cell lines and in the presence of CPT (Figure 6 ). Up to a 600% increase in DNA fragmentation, a marker of apoptosis, was measured using flow cytometry (Figure 7a ). ET-1, 8-CPT, and LPA each reduced basal apoptosis; however, in each case, anti-GEP overcame ligand protection and promoted a marked increase in apoptosis. This is further supported by net loss of cells and presence of nuclear condensation and apoptotic bodies shown by DAPI staining of antibody-treated cells (Figure 7b, c) . These results coupled with our prior findings (Jones et al., 2003) demonstrate that GEP is both a growth factor and a survival factor for ovarian cancer cells.
Discussion
Investigation into the driving forces underlying ovarian cancer have shown that LPA and ET-1 are autocrine growth and survival factors both in culture and in vivo (Bagnato et al., 1997; Mills and Moolenaar, 2003) . The downstream effectors of these growth factors have not been elucidated fully. We hypothesized that production of GEP in response to stimulation by LPA and ET-1 is a mechanism through which their stimulation signal is amplified and propagated. LPA and ET-1 signal through G protein-coupled receptors and their canonical second messengers (Mills and Moolenaar, 2003; Nicosia et al., 2003; Rosano et al., 2003) . We show that GEP induction occurs in response to LPA, ET-1, and cAMP/EPAC/MAPK (summarized in Figure 8) ; it is possible that ET-1 may signal GEP production through cAMP, however unlikely for LPA. 8-CPT, an EPACselective cAMP analog, promoted GEP, confirming activity of this pathway. This result is complemented by the paradoxical increase in GEP production in the presence of the PKA inhibitor H89, suggesting binding of available cAMP by EPAC. The BAPTA results invoke a role for cytosolic calcium, indicate that GEP production may occur downstream of several key signaling pathways. The ability of neutralizing anti-GEP antibodies to abrogate basal and ET-1, LPA, and 8-CPT induced cell growth and viability indicates that GEP is involved in the mechanism(s) of the growth factor activation pathways. A role for GEP as a prosurvival agent is confirmed by the demonstrations of , and LPA (c) stimulation of cell proliferation is GEP-dependent. OVCAR3 cells were starved then exposed to stimulant in the presence or absence of neutralizing anti-GEP antibody (5 ml). A dose-dependent and statistically significant inhibitory effect of the antibodies was observed in neutralization of growth with a maximal effect at 5 ml for each antibody (data not shown). Results are presented as mean and standard error of the mean of at least three replicate experiments using at least two independent purifications of antipeptide antibody GEP is an EPAC/MAPK-induced ovarian cancer survival factor M Kamrava et al apoptosis induced by anti-GEP antibodies. These data indicate that GEP, through cAMP/EPAC-mediated production, is part of the growth factor cascade that supports ovarian cancer growth and promotes ovarian cancer survival. LPA and ET-1 are well-described contributors to ovarian cancer development and progression. LPA signaling causes cell proliferation, cell survival, drug resistance, and proangiogenic, motility and invasionstimulating activities (Xu et al., 1995; Fang et al., 2002; Mills and Moolenaar, 2003; Nicosia et al., 2003) . ET-1, signaling through the ET-A receptor, also contributes to ovarian cancer tumor growth, survival, angiogenesis, and invasion (Bagnato et al., 1995 (Bagnato et al., , 1997 (Bagnato et al., , 1999 Rosano et al., 2001 Rosano et al., , 2003 Del Bufalo et al., 2002a) . Our hypothesis anticipated that LPA and ET-1 effects on ovarian cancer occur, at least in part, through signal amplification by LPA and ET-1 induced production of other growth factors, such as GEP. There is emerging precedent that growth factor stimulation can both transactivate other growth factor receptors and stimulate production of cytokines and growth factors. Transactivation has been shown between receptor tyrosine kinases and G protein-coupled receptors such as ET-A with EGFR or LPA with PDGFR (Daub et al., 1996; Herrlich et al., 1998; Vacca et al., 2000) . LPA and ET-1 have been shown to promote production of VEGF, IL-8, and the insulin-like growth factors (Goetzl et al., 1999; Salani et al., 2000; Mills and Moolenaar, 2003) . We now show that GEP production falls into this category of growth factor-stimulated growth factor production and signal amplification with production of ET-1 in response to LPA and GEP production through both.
Further dissection of the signaling pathways responsible for GEP production led to the demonstration that the cAMP/EPAC/MAPK, not PKA, pathway was involved in GEP expression. PKA is the classical intracellular cAMP receptor and has been shown to be upregulated in a number of cancers, including ovarian cancer (Alper et al., 1999; Amsterdam et al., 1999; McDaid et al., 1999) . Studies using a cAMP response element (CRE)-decoy in ovarian cancer cells have shown that the subset of genes activated by CRE are critical to controlling apoptosis, growth, and invasion (Alper et al., 1999) . We found that inhibition of PKA by exposure to H89 led to a paradoxical dose-dependent increase in GEP production. The importance of PKAindependent pathways in ovarian cancer has not been identified previously. cAMP can also exert effects through the lesser characterized PKA-independent EPAC pathway (Bos, 2003; Kopperud et al., 2003; Rangarajan et al., 2003) . Expression of PKA antisense has been shown to upregulate Rap-1, the target of EPAC, the alternative intracellular cAMP receptor (Cho et al., 2001) . EPACs are guanine nucleotide exchange factors for the Ras-like small GTPases Rap-1 and Rap-2. 8-CPT is a cAMP analog that specifically activates the EPAC pathway independently of PKA activation (Kang et al., 2003) . 8-CPT treatment of the ovarian cancer cell lines resulted in production and secretion of GEP, indicating involvement of the EPAC pathway in GEP production. This suggests that the induction of GEP in response to PKA inhibition with H89 may have been due to utilization of cAMP by the EPAC pathway. The loss of GEP production after inhibition of MEK provides further support for these observations. Prior studies have shown activation of the MAPK pathway when GEP was present as a ligand (Zanocco-Marani et al., 1999) . Together, this suggests that the interaction of GEP and the MAPK pathway may result in a feed-forward loop.
We have shown previously that reduction in GEP is associated with loss of capacity for proliferation, thymidine incorporation, and colonization in soft agar (Jones et al., 2003) . We have had persistent difficulty in generating viable stable cell lines with forced expression of antisense GEP. Reduction in activation of Akt was observed in the limited passages of the antisense transfectants that survived to be studied. This observation, coupled with our current findings that neutralization of GEP with the polyclonal antibodies stimulates apoptosis, supports that GEP is functioning in the cell as both a proliferation and survival factor. cAMP has been shown to differentially regulate Akt activation GEP is an EPAC/MAPK-induced ovarian cancer survival factor M Kamrava et al through PKA and EPAC (Mei et al., 2002) . Binding and activation of PKA caused inhibition of phosphorylation of Akt and reduced survival messages, whereas, binding to EPAC and activation of the Rap-1/MAPK cascade stimulated upregulation of phospho-Akt in a phosphatidylinositol 3 0 kinase-dependent fashion . We found marked reduction in MAPK activation in cells treated with BAPTA to abrogate the GEP response to LPA, indicating a role for MAPK downstream of LPA in the GEP production pathway. Further, LPA and ET-1 induction of GEP was partially inhibited by treatment with the PI3K inhibitor, LY294002 (data not shown), consistent with the pathways presented in this and prior reports. OVCAR3 cells were exposed to culture conditions with the inclusion of 8-CPT, ET-1, or LPA in the presence or absence of anti-GEP as indicated. Cells were subjected to FACS analysis and the sub G1/G0 fraction quantitated as a measure of DNA fragmentation. Data are presented as % of control apoptosis and are representative of at least three independent experiments. B/C. Nuclear condensation and apoptosis in response to anti-GEP. Hey-A8 (b) and OVCAR (c) cells were exposed to anti-GEP antibodies in the presence or absence of 8-CPT, ET-1, or LPA for 18 h followed by staining with DAPI and review. Apoptosis is represented both by apoptotic bodies indicated by the white arrows and by net loss of cells due to loss of attachment to the collagen-coated coverslip
The expression of GEP and thus GEP-mediated cell proliferation and survival are regulated through both cAMP and MAPK-mediated signaling pathways. This suggests that a combinatorial approach to inhibition of both of these pathways may also be an effective strategy in treating ovarian cancer. Recent mathematical modeling suggests that partial abrogation of multiple signaling pathways in series or parallel may yield augmented inhibition of the target end point . Thus, combining inhibitors of the cAMP and MAPK pathways could result in a greater blockade of GEP production in concert with inhibition of another growth factor pathway in ovarian cancer. Applications of this approach may also include antibody blockade of GEP in combination with endothelin receptor small molecule antagonists (see Salani et al. (2002) , for example) and may yield greater benefit than otherwise anticipated. Work is ongoing to translate our findings with the neutralizing polyclonal antibodies into preclinical and clinical models.
Materials and methods
Materials and cell culture
LPA, ET-1, 3-isobutyl-1-methylxanthine (IBMX), and other reagent grade agents were purchased from Sigma (St Louis, MO, USA). PTX, CTX, H-89, 8-CPT-2 0 -O-Me-cAMP (8-CPT), and U0126 were obtained from Calbiochem (La Jolla, CA, USA). Antibodies to cleaved caspase 3, ERK, and phospho-ERK were purchased from Cell Signaling (Beverly, MA, USA). Antibody to PARP was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). BCA protein reagent, protein A/G beads, ECL reagents, and control IgG were purchased from Pierce Biochemicals (Rockford, IL, USA). UltraspecRNA isolation kit was from Biotex (Houston, TX, USA). RediPrime II kit, 32 P dCTP, and RapidHyb buffer were obtained from Amersham (Piscataway, NJ, USA). Precast PAGE gels were from Invitrogen (San Diego, CA, USA). XTT (sodium-3 0 -[1-(phenylamino-carbonyl)-3-4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) labeling agent was obtained from Roche Applied Science (Indianapolis, IN, USA). Vectashield mounting medium for fluorescence for DAPI was purchased from Vector Laboratories (Burlingame, CA, USA) and propidium iodine and BAPTA-AM [bis-(2-aminophenoxy)ethane-N,N,N 0 ,N 0 -tetra acetate acetoxymethyl ester] was from Molecular Probes (Eugene, OR, USA).
OVCAR3 cells were obtained from the American Tissue Culture Collection (Manassas, VA, USA). HEY-A8 cells were a generous gift of Dr Gordon Mills (MD Anderson Cancer Center, Houston, TX, USA). All cell lines were cultured in RPMI 1640 with 10% FCS and penicillin and streptomycin unless otherwise indicated.
Cell treatments
HEY-A8 and OVCAR3 cells were grown overnight in serumcontaining RPMI 1640, washed twice with PBS and then incubated with serum-free (SF) RPMI 1640 for a 6 h starvation period. Medium was removed and plates were washed twice with SF-RPMI. Cells were then treated with indicated concentrations of reagents in SF-RPMI 1640 as described. Cells were incubated for 24 h before lysis or staining unless otherwise indicated. DMSO 0.1% was used as the vehicle control in experiments containing H89, IBMX, BAPTA, and U0126. An IgG control was included when cells were treated with peptide-purified antipeptide antibodies. Generation and peptide affinity purification of a GEP polyclonal antibody (Ab736) was described previously (Jones et al., 2003) . Ab736 recognizes the 68 kDa unglycosylated GEP, as well as various glycosylated forms of higher molecular weight. This antibody poorly recognizes granulins, migrating as 14 kDa bands . A second antipeptide antibody, Ab737, shown to recognize both GEP and granulins, and capable of immunoprecipitation, was used (Davidson et al., 2004) .
Conditioned media, cellular protein, and RNA isolation CM was collected prior to cell lysis. Protease inhibitors (PI; final concentration 10 mM PMSF (phenylmethylsulfonyl fluoride), 10 mg/ml aprotinin, and 10 mg/ml leupeptin) were added to CM prior to centrifugation, aliquoting and freezing at À801C. Total cell lysates were prepared using modified RIPA buffer (50 mMTris-HCL, pH 7.5, 0.1% Na deoxycholate, 10 mM Na pyrophosphate, 2 mM Na 3 VO 4 , 150 mM NaCl, 4 mM EDTA, 1% NP-40, 1 mM PMSF, 10 mg/ml aprotinin, and 10 mg/ml leupeptin). Lysates were sonicated with an ultrasonic dismembranator and protein concentrations determined using the BCA protein assay. Proteins were subjected to no more than one freeze/thaw cycle. Total cellular RNA was prepared from parallel cell cultures with UltraspecRNA according to manufacturer's recommendations.
Northern and Western blots
RIPA protein lysates were subjected to PAGE electropheresis, transferred to nylon membranes, which were then blocked, washed and probed with indicated primary antibodies. Reducing sample buffer was supplemented with 8 M urea for Figure 8 A model for GEP production through cAMP/MAPK pathways. LPA can produce ET-1 which makes some cAMP. LPA requires calcium mobilization and MAPK activity for GEP production. cAMP drives GEP through activation of EPAC in a MEK-sensitive fashion. Thus, GEP production is sensitive to stimulation of the cAMP-EPAC, cytosolic calcium, and MAPK pathways, through LPA, ET-1 and other growth factor receptor activation. GEP is important for ovarian cancer survival as shown by apoptosis in response to its immunoneutralization lysates to be probed for PARP. Complexes were visualized by enhanced chemiluminescence detection. Where indicated, unconcentrated CM (1 ml) or lysate aliquots were immunoprecipitated with Ab737 overnight at 41C, captured with protein A/G beads, then washed four times with NP-40 lysis buffer (PI þ 20 mM Tris-HCL pH8.0, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA) and twice with PBS þ PI. Immunoprecipitates were subjected to reducing gel electrophoresis followed by immunoblot. All blots are representative of at least three replicate experiments.
Denatured total RNA was electrophoresed in agarose formaldehyde-denaturing gels followed by capillary transfer to nylon membrane and ultraviolet crosslinking to membrane. Blots were hybridized with a labeled 1.8 kb GEP probe (Jones et al., 2003) , washed to high stringency and put to film. All blots are representative of at least three replicate experiments.
Cell proliferation assays
OVCAR3 and HEY-A8 cells were seeded in 96-well tissue culture plates at 8000 and 4000 cells/well, respectively. After overnight culture, cells were starved in SF medium for 24 h then exposed to 300 mM 8-CPT, 50 nM ET-1, or 20 mM LPA in the presence or absence of anti-GEP antibody or control IgG. Medium was removed 48 h later and the viability of the cells was measured using the XTT assay as per the manufacturer's instructions. Data are presented as percent of control and incorporates or represents at least three experiments.
Fluorescence microscopy
OVCAR-3 and Hey-A8 cells were grown on 0.1% gelatincoated coverslips overnight, subjected to serum starvation, then treated with indicated reagents in a serum-free background for 18 h. Plates were washed twice with PBS, incubated in 3.7% formaldehyde for 10 min, washed again and then permeabilized with Triton X-100 0.1% for 5 min. Coverslips were mounted onto slides with DAPI stain mounting medium and imaged. The results presented are representative of at least three independent experiments.
Flow cytometric analysis of apoptosis
OVCAR-3 and Hey-A8 were cultured overnight, serum starved for 6 h, then incubated with the indicated reagents for 24 h prior to harvesting of floating and adherent cells. Cells were fixed with 70% ethanol overnight then pellets collected by centrifugation. RNAase 1000 units/ml final volume was added, followed by propidium iodide 50 mg/ml. Samples were subjected to flow cytometric analysis using CellQuest (BD Biosciences, San Jose, CA, USA). FlowJo (Tree Star Inc., San Carlos, CA, USA) and ModFit software (Verity Software House, Inc., Topsham, ME, USA) were used for cell cycle analysis.
Statistical analysis
Results were analyzed using Prism (GraphPad, San Diego, CA, USA). Unpaired Student's t-tests were applied to replicate experiments. Two-sided P-values are reported.
